PGD is now performed for 357 different conditions, with over 99.5% accuracy in the leading PGD centers.
There is also no restriction in provision of PGD, which may presently be performed for any genetic condition, even in cases that the genetic condition is first identified in one of the parents or only in the affected child. Indications for PGD are steadily expanding, with current wider application of PGD to diseases with genetic predisposition, such as different cancers and cardiovascular disorders, so PGD centers will face a forthcoming increase of PGD requests from this highly sensitive group of at risk couples. Despite recent controversy in PGD for chromosomal disorders, the present progress in improving the accuracy of the procedure through adequate choice of biopsy material and microarray analysis for 24 chromosomes demonstrated the obvious clinical impact of avoiding the transfer of
aneuploid embryos. A major breakthrough has been in the development and application of microarray technology for PGD of chromosomal disorders, allowing a highly improved detection of chromosomally abnormal oocytes and embryos, resulting in a higher accuracy and improved clinical outcome following the application of 24-chromosome aneuploidy testing coupled with blastocyst biopsy.